Ceftazidime-avibactam

The increase in nosocomial infections by beta-lactamase-producing Gram-negative bacilli constitutes a therapeutic challenge. The combination of ceftazidime-avibactam offers a very interesting therapeutic option for nosocomial pneumonia caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, multidrug-resistant Pseudomonas aeruginosa, and other enterobacteria. Compared to carbapenems, ceftazidime-avibactam has demonstrated non-inferiority in the treatment of nosocomial pneumonia including better clinical and microbiological cure rates and mortality compared to colistin. The limitation of ceftazidime-avibactam in the treatment of infections caused by metallo-beta-lactamase-producing Enterobacteriaceae can be overcome with the addition of aztreonam.

Automated summary

The combination therapy of ceftazidime-avibactam offers an interesting therapeutic option for nosocomial pneumonia caused by beta-lactamase-producing Gram-negative bacilli. It has shown non-inferiority compared to carbapenems, with better cure rates and mortality compared to colistin. The limitation of ceftazidime-avibactam in treating infections caused by metallo-beta-lactamase-producing Enterobacteriaceae can be overcome by adding aztreonam.